dermatology drugs

Oral Ivermectin Therapeutic Cheat Sheet
Oral IvermectinIvermectin is a semi-synthetic derivative of avermectins, a class of macrocyclic lactones with broad-spectrum anti-parasitic effects. Its unique mechanism of action, favorable safety profile, and anti-inflammatory properties make ivermectin invaluable in the treatment of a wide range of cutaneous parasitic infestations, including scabies. We continue our series, Therapeutic Cheat Sheet, with a cl …
Oral Ivermectin
Ritlecitinib Therapeutic Cheat Sheet
RitlecitinibAlopecia areata (AA) is a nonscarring alopecia driven by autoreactive cytotoxic CD8 T cells against hair follicle antigens. With an unpredictable clinical course, which can include alopecia totalis and universalis, AA can be debilitating to patients’ quality of life. Historically, glucocorticosteroids, cyclosporine, methotrexate, and azathioprine were used off-label for non-targeted immunosuppre …
Ritlecitinib
Topical Metronidazole Therapeutic Cheat Sheet
topical metronidazoleMetronidazole is a nitroimidazole with antiprotozoal, antibacterial, and anti-inflammatory properties and is available in oral and topical formulations. The diverse mechanisms of action of metronidazole have expanded its utility across various dermatologic conditions. Topical metronidazole is well tolerated and has demonstrated improvements in inflammatory papules and pustules of rosacea. We conti …
topical metronidazole
Cemiplimab Therapeutic Cheat Sheet
CemiplimabCemiplimab is a monoclonal antibody therapy that has emerged as a promising treatment option for certain types of advanced skin cancer. Specifically designed to target the programmed cell death protein 1 (PD-1) pathway, cemiplimab works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby unleashing the body's immune system to recognize and attack cancer cells. We con …
Cemiplimab
Sonidegib Therapeutic Cheat Sheet
SonidegibBasal cell carcinoma (BCC) is the most common human cancer. When curative surgery and radiotherapy are contraindicated, systemic agents targeting the hedgehog signaling pathway are invaluable options for this subset of adult patients with locally advanced BCC (laBCC). Vismodegib and sonidegib are oral options with similar efficacy and side effect profiles. With the absence of head-to-head comparis …
Sonidegib